Pharmaceutical and biomedical industries have long relied on animal-derived materials, but concerns over supply stability, safety, tighter regulation and ethical issues are increasing constraints, CellWeavers says. The startup is developing cell-culture-based specialty bio materials, including a cultured LAL endotoxin test material and cultured heparin. Chief executive Kondition Sik (조건식) says the company is redesigning supply from animals to animal cells. CellWeavers has completed seed funding, was selected for TIPS and won an entrepreneurship contest award.